Netilmicin sulfate as single-agent therapy for Pseudomonas infections

R. N. Greenberg, J. N. Hansbrough, R. R. Lorber, G. H. Miller

Research output: Contribution to journalArticlepeer-review


In a prospective multicenter clinical trial, 69 patients with Pseudomonas infections were treated with netilmicin sulfate as the only antipseudomonal antibiotic. Clinical resolution or improvement was observed for 81% of the infections, whereas 19% were considered treatment failures. The bacteriologic response, based on follow-up culture results, showed elimination of Pseudomonas from 62% of the infection sites, with persistence in 30%. All isolates were susceptible by disk susceptibility testing (zone ≥15 mm), and by microdilution testing in unsupplemented broth. The majority of isolates, however, were resistant in cation supplemented media. The clinical failures could be accounted for by factors other than netilmicin failure. In conclusion, netilmicin appeared effective as treatment for netilmicin-susceptible Pseudomonas infections in nonneutropenic adults. A low incidence of nephrotoxicity (12%) occurred despite careful monitoring of serum levels.

Original languageEnglish
Pages (from-to)715-718
Number of pages4
JournalSouthern Medical Journal
Issue number6
StatePublished - 1989

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Netilmicin sulfate as single-agent therapy for Pseudomonas infections'. Together they form a unique fingerprint.

Cite this